# A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)

Source: https://onco.cc/trials/nct07593144/  
OnCo record `nct07593144` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of FS-207 run by Foresight Therapeutics (Hefei) Co., Ltd., not yet recruiting.

## Summary

A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H) is a phase 1 interventional study registered as NCT07593144 by Foresight Therapeutics (Hefei) Co., Ltd., with 156 participants planned, started 2026-05-15. Conditions recorded: Advanced Solid Tumors. Interventions recorded: FS-207.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07593144
- Phase: 1
- Setting: A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)
- Sponsor: Foresight Therapeutics (Hefei) Co., Ltd.
- Enrolled: 156

## Sources

- ClinicalTrials.gov NCT07593144: https://clinicaltrials.gov/study/NCT07593144

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [FS-207](https://onco.cc/drugs/fs-207/)
- companies: [Fushi Biotechnology](https://onco.cc/companies/fushi-biotechnology/)

---
JSON: https://onco.cc/api/v1/entities/nct07593144.json